Liraglutide Not Tied to Higher Risk of Cardiovascular Events

This article originally appeared here.
Share this content:
Liraglutide Not Tied to Higher Risk of Cardiovascular Events
Liraglutide Not Tied to Higher Risk of Cardiovascular Events

FRIDAY, Oct. 13, 2017 (HealthDay News) -- Liraglutide treatment for weight management is not associated with increased risk of cardiovascular events, according to a study published online Sept. 26 in Diabetes, Obesity and Metabolism.

Melanie J. Davies, M.D., from the University Hospitals of Leicester NHS Trust in the United Kingdom, and colleagues conducted post hoc analysis using data from 5,908 participants in five randomized, double-blind, placebo-controlled clinical trials of liraglutide, a glucagon-like peptide-1 receptor agonist approved for weight management, in order to assess cardiovascular risk.

The researchers found that with liraglutide (3.0 mg), eight participants had positively adjudicated cardiovascular events (1.54 events/1,000 person-years), compared to 10 participants in the comparators group (3.65 events/1000 person-years). Compared to the non-liraglutide group, the hazard ratio for 3.0 mg liraglutide treatment was 0.42 (95 percent confidence interval, 0.17 to 1.08).

"In this analysis, liraglutide 3.0 mg treatment was not associated with excess cardiovascular risk," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which manufactures liraglutide and sponsored the trials.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC Issues Warning on Contaminated Raw Milk

CDC Issues Warning on Contaminated Raw Milk

Case of New Jersey woman becoming ill after drinking raw milk from Udder Milk company

Cerebral Morphometric Changes Discriminate ADHD, Controls

Cerebral Morphometric Changes Discriminate ADHD, Controls

Alterations discern ADHD-I, ADHD-C, with discriminating features located in DMN, insular cortex

Baby Boomers Have Increased Risk of Rx Opioid Overdose Death

Baby Boomers Have Increased Risk of Rx Opioid ...

In addition, those born from 1947 to 1964 and 1979 to 1992 have increased risk of heroin overdose death

is free, fast, and customized just for you!

Already a member?

Sign In Now »